The company has raised approximately $300M in equity capital over three days, following positive Phase 3 data. Monitor for updates on GPS clinical development and commercialization plans, as well as potential further dilution if the company continues to tap the equity markets.
Drugs in focus
SLS drug pipeline →galinpepimut-S
● Neutral Named in this 8-K- Impact
- Phase
- Phase 3
- Time to market
- If the Phase 3 REGAL trial succeeds, the earliest potential regulatory submission (BLA) would follow the topline readout in Q4 2026, with an FDA review timeline of roughly 10-12 months thereafter, putting a potential approval in late 2027 or early 2028 at the earliest.
- Next catalyst
- None dated
What to watchWatch for the topline Phase 3 REGAL overall survival readout, expected within the next two months (Q4 2026). A positive result showing statistically significant survival benefit could drive the stock toward analyst targets of $30-$35, while a miss or marginal result would likely devastate the stock given the company's pre-revenue status and dependence on this single asset. The ongoing securities investigation adds a secondary legal risk to monitor.
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
SELLAS Life Sciences priced a $150M underwritten public offering of 11,538,462 shares at $13.00 per share, with a 30-day underwriter option for up to 1,730,769 additional shares. The offering closed on November 20, 2026, raising approximately $161.8M in net proceeds including the full exercise of the option, to fund clinical development and commercialization activities following positive Phase 3 REGAL trial results.
Key Financial Metrics
Key Facts
- Priced 11,538,462 shares at $13.00 per share, a 27.6% discount to the prior day's $17.95 close
- Underwriters have a 30-day option to purchase up to 1,730,769 additional shares at the same price
- Net proceeds of approximately $161.8M including full exercise of the option
- Underwriters include J.P. Morgan, TD Cowen, Mizuho, A.G.P./Alliance Global Partners, and Maxim Group
- Offering closed on November 20, 2026
- Proceeds will fund clinical development and commercialization activities
- This is the second capital raise in three days, following a $150M offering priced on November 19, 2026
Financial Impact
$150M gross proceeds, approximately $161.8M net proceeds including full option exercise
Risk Factors
- Significant dilution to existing shareholders from two offerings totaling approximately $300M
- The 27.6% discount to the prior close signals aggressive pricing and potential downward pressure on the stock
- Rapid capital raises may indicate urgency to fund operations or commercialization ahead of revenue generation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-130331 |
| Document: tm2630303d1_8k.htm | 0001104659-26-130331 |
| Document: tm2630303d1_ex5-1.htm | 0001104659-26-130331 |
| Document: tm2630303d1_ex99-1.htm | 0001104659-26-130331 |
| Document: 0001104659-26-130331-index-headers.html | 0001104659-26-130331 |
| Document: 0001104659-26-130331-index.html | 0001104659-26-130331 |
| Document: 0001104659-26-130331.txt | 0001104659-26-130331 |
Track record
19 reports on SLS
4 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +63.62% at T+60 after the Mar 12, 2026 report. 4 of 6 went positive at some point.
Filters
- Nov 20, 20262d ago 8-K Bearish 6/10 Viewing Entry $14.80 Now $13.66 +7.70% settles Nov 23
- Nov 19, 20262d ago 424B5 Bearish 6/10 Entry $14.86 Now $13.66 +8.08% settles Nov 23
- Nov 18, 20263d ago Press Release Bearish 6/10 Entry $14.86 to $13.66 Now $13.66 +8.08% ▲ +8.08% +4.43% vs SPY
- Nov 17, 20264d ago 424B5 Bearish 6/10 Entry $17.95 to $14.86 Now $13.66 +23.90% ▲ +17.21% +15.25% vs SPY
- Nov 17, 20264d ago Press Release Bearish 6/10 Entry $17.95 to $14.86 Now $13.66 +23.90% ▲ +17.21% +15.25% vs SPY
- Nov 17, 20265d ago 8-K Bullish 7/10 Entry $19.15 to $17.95 Now $13.66 −28.67% ▼ −6.27% −5.96% vs SPY
- Nov 17, 20265d ago Press Release Bullish 8/10 Entry $19.15 to $17.95 Now $13.66 −28.67% ▼ −6.27% −5.96% vs SPY
- Nov 12, 20269d ago 8-K Neutral 5/10 Entry $7.86 to $7.47 Now $13.66 +73.79% ▼ −4.96% −3.05% vs SPY
- Nov 10, 202611d ago SC 13G Neutral 3/10 Entry $8.37 to $8.42 Now $13.66 +63.20% ▲ +0.60% −0.72% vs SPY
- Nov 3, 202618d ago Institutional Cluster Neutral 3/10 Entry $8.87 to $9.14 Now $13.66 +54.00% ▲ +3.04% +1.39% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers